<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344823</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT: 2010-023420-25</org_study_id>
    <nct_id>NCT02344823</nct_id>
  </id_info>
  <brief_title>Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis</brief_title>
  <official_title>Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to analyze the effect of Vardenafil on Erectile Dysfunstion and portal
      hemodynamics in patients with liver cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 Phase 2 arm study

      Phase A:

      Baseline HVPG (Hepatic Venous Pressure Measurement) measurement, followed by 1 capsule of
      10mg Vardenafil or Placebo (randomization 1:1) daily per oral for 7 days, HVPG measurement at
      day 7

      Phase B:

      1 capsule of 10mg Vardenafil or Placebo (randomization 1:1) ad libidum per oral for 28 days
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HVPG (Hepatic Venous Pressure Measurement)</measure>
    <time_frame>7 days</time_frame>
    <description>HVPG response to Vardenafil/Placebo at day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IIEF (International Index of Erectile Function ) 5</measure>
    <time_frame>28 days</time_frame>
    <description>IIEF 5 calculation after Vardenafil/Placebo both Phase A and B</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Vardenafil Phase A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Phase A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vardenfil Phase B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Phase B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vardenafil</intervention_name>
    <description>per oral intake of 10mg Vardenafil once daily</description>
    <arm_group_label>Vardenafil Phase A</arm_group_label>
    <arm_group_label>Vardenfil Phase B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG (Hepatic venous pressure measurement) baseline</intervention_name>
    <description>HVPG measurement day 1</description>
    <arm_group_label>Vardenafil Phase A</arm_group_label>
    <arm_group_label>Placebo Phase A</arm_group_label>
    <other_name>HVPG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG (Hepatic venous pressure measurement) day 7</intervention_name>
    <description>HVPG measurement day 7</description>
    <arm_group_label>Vardenafil Phase A</arm_group_label>
    <arm_group_label>Placebo Phase A</arm_group_label>
    <other_name>HVPG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>IIEF 5 (International Index of Erectile Function) questionaire baseline</intervention_name>
    <description>IIEF 5 questionaire to define level of erectile dysfunction at baseline</description>
    <arm_group_label>Vardenafil Phase A</arm_group_label>
    <arm_group_label>Placebo Phase A</arm_group_label>
    <arm_group_label>Vardenfil Phase B</arm_group_label>
    <arm_group_label>Placebo Phase B</arm_group_label>
    <other_name>IIEF 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>IIEF 5 (International Index of Erectile Function) questionnaire at study phase end</intervention_name>
    <description>IIEF 5 questionaire to define level of erectile dysfunction at end of study phase</description>
    <arm_group_label>Vardenafil Phase A</arm_group_label>
    <arm_group_label>Placebo Phase A</arm_group_label>
    <arm_group_label>Vardenfil Phase B</arm_group_label>
    <arm_group_label>Placebo Phase B</arm_group_label>
    <other_name>IIEF 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo intake once daily</intervention_name>
    <arm_group_label>Placebo Phase A</arm_group_label>
    <arm_group_label>Placebo Phase B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients aged older than 18 years with mild to moderate (Child´s Grade A or B)
             cirrhosis scheduled for hepatic hemodynamic investigation.

          -  Erectile dysfunction in medical history

          -  Following beta-blocker therapy will be allowed: carvedilol (up to the max. dose of 25
             mg) and propranolol (up to the max. dose of 160 mg)

          -  Patient living in a stable relationship

          -  HVPG (Hepatic Venous Pressure Measurement)&gt;= 10 mmHg

        Exclusion Criteria:

          -  HVPG &lt;10

          -  HVPG &gt; 20 mmHg and varices, unless ligated and treated in an eradication program
             within 6 months

          -  history of variceal bleeding without secondary prophylaxis with beta blocker or
             endoscopic band ligation

          -  History of endoscopically diagnosed large varices with red spots without previous
             bleeding and without prophylactic beta blocker or endoscopic band ligation

          -  History of hypersensitivity to the trial drugs and contrast agent or to drugs with a
             similar chemical structure

          -  Treatment with vasoactive or non-steroidal anti-inflammatory drugs or systemic
             antibiotics one week before the study

          -  Exclusion criteras for hepatic hemodynamic investigation

          -  Cardiac, renal or respiratory failure

          -  previous surgical or transjugular intrahepatic portosystemic shunt

          -  insulin-dependent diabetes

          -  Child´s Grade C cirrhosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <phone>+4314040047410</phone>
    <email>arnulf.ferlitsch@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Remy Schwarzer, MD</last_name>
    <phone>+4314040047410</phone>
    <email>remy.schwarzer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnulf Ferlitsch, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>47410</phone_ext>
      <email>arnulf.ferlitsch@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Arnulf Ferlitsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémy Schwarzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Arnulf Ferlitsch, MD</investigator_full_name>
    <investigator_title>Assoz. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>erectile dysfunction</keyword>
  <keyword>portal hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

